Haemonetics Corp
NYSE:HAE

Watchlist Manager
Haemonetics Corp Logo
Haemonetics Corp
NYSE:HAE
Watchlist
Price: 92.11 USD 0.36%
Market Cap: 4.7B USD
Have any thoughts about
Haemonetics Corp?
Write Note

Haemonetics Corp
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Haemonetics Corp
Cost of Revenue Peer Comparison

Comparables:
XRAY
ICUI
ALGN
LNTH
MMSI

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Haemonetics Corp
NYSE:HAE
Cost of Revenue
-$625.9m
CAGR 3-Years
-8%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Cost of Revenue
-$1.9B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-3%
ICU Medical Inc
NASDAQ:ICUI
Cost of Revenue
-$1.6B
CAGR 3-Years
-24%
CAGR 5-Years
-14%
CAGR 10-Years
-26%
Align Technology Inc
NASDAQ:ALGN
Cost of Revenue
-$1.2B
CAGR 3-Years
-8%
CAGR 5-Years
-13%
CAGR 10-Years
-21%
Lantheus Holdings Inc
NASDAQ:LNTH
Cost of Revenue
-$527.2m
CAGR 3-Years
-34%
CAGR 5-Years
-25%
CAGR 10-Years
-11%
Merit Medical Systems Inc
NASDAQ:MMSI
Cost of Revenue
-$705m
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
-10%

See Also

What is Haemonetics Corp's Cost of Revenue?
Cost of Revenue
-625.9m USD

Based on the financial report for Sep 28, 2024, Haemonetics Corp's Cost of Revenue amounts to -625.9m USD.

What is Haemonetics Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%

Over the last year, the Cost of Revenue growth was -7%. The average annual Cost of Revenue growth rates for Haemonetics Corp have been -8% over the past three years , -4% over the past five years , and -3% over the past ten years .

Back to Top